{"disease":{"id":"mixed-anxiety-and-depressive-disorder","name":"Mixed anxiety and depressive disorder","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":7,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"chlordiazepoxide","indication_name":"Mixed anxiety and depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chlordiazepoxide Hydrochloride","generic_name":"CHLORDIAZEPOXIDE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Benzodiazepine","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"maprotiline","indication_name":"Mixed anxiety and depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MAPROTILINE","company_name":"","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor","drug_class":"maprotiline","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"perphenazine","indication_name":"Mixed anxiety and depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trilafon","generic_name":"PERPHENAZINE","company_name":"","drug_phase":"marketed","molecular_target":"D(3) dopamine receptor","drug_class":"Phenothiazine [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"amitriptyline","indication_name":"Mixed anxiety and depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Endep","generic_name":"AMITRIPTYLINE","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Histamine H1 receptor","drug_class":"Tricyclic Antidepressant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"amitryptiline","indication_name":"Mixed anxiety and depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Amitryptiline","company_name":"Mahatma Gandhi Institute of Medical Sciences","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, 5-hydroxytryptamine receptor 6, D(1B) dopamine receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"xanax","indication_name":"Mixed anxiety and depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xanax","company_name":"National Taiwan University Hospital","drug_phase":"marketed","molecular_target":"Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"alprazolam","indication_name":"Mixed anxiety and depressive disorder","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xanax","generic_name":"alprazolam","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Bromodomain-containing protein 4, Platelet-activating factor receptor, Cytochrome P450 3A4","drug_class":"Benzodiazepine (triazolobenzodiazepine)","quality_score":0,"revenue":null,"mechanism":"Short-acting, high-potency benzodiazepine that enhances GABA-A receptor activity, providing rapid anxiolytic relief."}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}